We advised Emergent BioSolutions (NYSE:EBS) on the government contract aspects of two transactions involving the acquisition of assets related to medical countermeasures used by the U.S. government. These transactions expand Emergent’s portfolio of approved medical countermeasures addressing Category A bioterrorism threats.
Emergent BioSolutions purchased the assets related to raxibacumab, a countermeasure approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax, from GlaxoSmithKline (LSE/NYSE:GSK). Emergent will assume responsibility for GSK’s multi-year supply contract with the Biomedical Advanced Research and Development Authority (BARDA) for raxibacumab, which will be used to further supply the U.S. Strategic National Stockpile (SNS). BARDA, a division of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, procures antibiotics, vaccines, chemical antidotes, antitoxins, and other critical equipment and supplies for the SNS.
Emergent BioSolutions also purchased the assets related to ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live), the only FDA-approved smallpox vaccine, from Sanofi. Emergent will assume responsibility for an existing 10-year contract with the Centers for Disease Control and Prevention (CDC) for the delivery of ACAM2000 to the SNS and establishing U.S.-based manufacturing of ACAM2000. More than 230 million doses have been supplied to the SNS to date.
Emergent BioSolutions is a global life sciences company that seeks to protect and enhance life by focusing on providing medical countermeasures for civilian and military populations that address accidental, intentional, and naturally emerging public health threats.